136 related articles for article (PubMed ID: 15179033)
1. Mechanism of transcriptional repression by TEL/RUNX1 fusion protein.
Lee YJ; Kim JH; Bae S; Rho SK; Choe SY
Mol Cells; 2004 Apr; 17(2):217-22. PubMed ID: 15179033
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins.
Heibert SW; Lutterbach B; Durst K; Wang L; Linggi B; Wu S; Wood L; Amann J; King D; Hou Y
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S31-4. PubMed ID: 11587363
[TBL] [Abstract][Full Text] [Related]
3. Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein.
Fenrick R; Amann JM; Lutterbach B; Wang L; Westendorf JJ; Downing JR; Hiebert SW
Mol Cell Biol; 1999 Oct; 19(10):6566-74. PubMed ID: 10490596
[TBL] [Abstract][Full Text] [Related]
4. Correlation between cellular localization of TEL/AML1 fusion protein and repression of AML1-mediated transactivation of CR1 gene.
Rho JK; Kim JH; Yu J; Choe SY
Biochem Biophys Res Commun; 2002 Sep; 297(1):91-5. PubMed ID: 12220513
[TBL] [Abstract][Full Text] [Related]
5. ETO, but not leukemogenic fusion protein AML1/ETO, augments RBP-Jkappa/SHARP-mediated repression of notch target genes.
Salat D; Liefke R; Wiedenmann J; Borggrefe T; Oswald F
Mol Cell Biol; 2008 May; 28(10):3502-12. PubMed ID: 18332109
[TBL] [Abstract][Full Text] [Related]
6. TEL/AML1 shows dominant-negative effects over TEL as well as AML1.
Gunji H; Waga K; Nakamura F; Maki K; Sasaki K; Nakamura Y; Mitani K
Biochem Biophys Res Commun; 2004 Sep; 322(2):623-30. PubMed ID: 15325275
[TBL] [Abstract][Full Text] [Related]
7. Recruitment of the nuclear receptor corepressor N-CoR by the TEL moiety of the childhood leukemia-associated TEL-AML1 oncoprotein.
Guidez F; Petrie K; Ford AM; Lu H; Bennett CA; MacGregor A; Hannemann J; Ito Y; Ghysdael J; Greaves M; Wiedemann LM; Zelent A
Blood; 2000 Oct; 96(7):2557-61. PubMed ID: 11001911
[TBL] [Abstract][Full Text] [Related]
8. Multiple subnuclear targeting signals of the leukemia-related AML1/ETO and ETO repressor proteins.
Barseguian K; Lutterbach B; Hiebert SW; Nickerson J; Lian JB; Stein JL; van Wijnen AJ; Stein GS
Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15434-9. PubMed ID: 12427969
[TBL] [Abstract][Full Text] [Related]
9. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.
Wichmann C; Chen L; Heinrich M; Baus D; Pfitzner E; Zörnig M; Ottmann OG; Grez M
Cancer Res; 2007 Mar; 67(5):2280-9. PubMed ID: 17332359
[TBL] [Abstract][Full Text] [Related]
10. Acetylation inactivates the transcriptional repressor BCL6.
Bereshchenko OR; Gu W; Dalla-Favera R
Nat Genet; 2002 Dec; 32(4):606-13. PubMed ID: 12402037
[TBL] [Abstract][Full Text] [Related]
11. Acetylation-mediated transcriptional activation of the ETS protein ER81 by p300, P/CAF, and HER2/Neu.
Goel A; Janknecht R
Mol Cell Biol; 2003 Sep; 23(17):6243-54. PubMed ID: 12917345
[TBL] [Abstract][Full Text] [Related]
12. AML-2 is a potential target for transcriptional regulation by the t(8;21) and t(12;21) fusion proteins in acute leukemia.
Meyers S; Lenny N; Sun W; Hiebert SW
Oncogene; 1996 Jul; 13(2):303-12. PubMed ID: 8710369
[TBL] [Abstract][Full Text] [Related]
13. Multiple regions of ETO cooperate in transcriptional repression.
Hildebrand D; Tiefenbach J; Heinzel T; Grez M; Maurer AB
J Biol Chem; 2001 Mar; 276(13):9889-95. PubMed ID: 11150306
[TBL] [Abstract][Full Text] [Related]
14. The nuclear receptor co-repressor (N-CoR) utilizes repression domains I and III for interaction and co-repression with ETO.
Lausen J; Cho S; Liu S; Werner MH
J Biol Chem; 2004 Nov; 279(47):49281-8. PubMed ID: 15377655
[TBL] [Abstract][Full Text] [Related]
15. Molecular targeting of aberrant transcription factors in leukemia: strategies for RUNX1/ETO.
Wichmann C; Grez M; Lausen J
Curr Drug Targets; 2010 Sep; 11(9):1181-91. PubMed ID: 20583973
[TBL] [Abstract][Full Text] [Related]
16. Molecular basis for a dominant inactivation of RUNX1/AML1 by the leukemogenic inversion 16 chimera.
Huang G; Shigesada K; Wee HJ; Liu PP; Osato M; Ito Y
Blood; 2004 Apr; 103(8):3200-7. PubMed ID: 15070703
[TBL] [Abstract][Full Text] [Related]
17. The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription.
Hiebert SW; Sun W; Davis JN; Golub T; Shurtleff S; Buijs A; Downing JR; Grosveld G; Roussell MF; Gilliland DG; Lenny N; Meyers S
Mol Cell Biol; 1996 Apr; 16(4):1349-55. PubMed ID: 8657108
[TBL] [Abstract][Full Text] [Related]
18. The MYND motif is required for repression of basal transcription from the multidrug resistance 1 promoter by the t(8;21) fusion protein.
Lutterbach B; Sun D; Schuetz J; Hiebert SW
Mol Cell Biol; 1998 Jun; 18(6):3604-11. PubMed ID: 9584201
[TBL] [Abstract][Full Text] [Related]
19. TEL-AML1 preleukemic activity requires the DNA binding domain of AML1 and the dimerization and corepressor binding domains of TEL.
Morrow M; Samanta A; Kioussis D; Brady HJ; Williams O
Oncogene; 2007 Jun; 26(30):4404-14. PubMed ID: 17237815
[TBL] [Abstract][Full Text] [Related]
20. The leukemia-associated gene TEL encodes a transcription repressor which associates with SMRT and mSin3A.
Chakrabarti SR; Nucifora G
Biochem Biophys Res Commun; 1999 Nov; 264(3):871-7. PubMed ID: 10544023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
